BRCA1 and Familial prostate cancer: Variations between PARPi include differing abilities to inhibit enzymatic activity, PARP-trapping ability, and drug distribution within tissue; however, the clinical implications of these measures on both efficacy and toxicity is less well defined, with most PARPi showing an ORR in the range of 34.2–52% in BRCA1/2 altered prostate cancer [3,5,6,7,34,35,36,37,38,39].